127 filings
Page 2 of 7
6-K
gia7b xb256yr8lf
28 Mar 23
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
4:37pm
6-K
v4a6pzq4
21 Mar 23
Current report (foreign)
6:48am
6-K
81ejtza8j36
10 Nov 22
Current report (foreign)
4:10pm
6-K
cabvelz4
10 Nov 22
Current report (foreign)
4:06pm
6-K
cl7s4t4w 6gjn5s2
2 Nov 22
Current report (foreign)
4:17pm
6-K
gc0x0ir
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
mhcvmh8 5b
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
gn1atmotlenh5hrc
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
wtr0d 1qoc8v
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
v99v6emormr 0s
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
6-K
ilw2covhbi5b7 eq
3 Oct 22
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
5:43pm
6-K
wyl3e1
26 Sep 22
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by
7:18am
6-K
16do7b86ex
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
8drhhqy
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
gyih9a05 dgc
22 Aug 22
Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders
4:06pm
6-K
l7rxojn1g4s5
5 Jul 22
Current report (foreign)
4:15pm
6-K
gdyi s04lo
2 Jun 22
Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
9:07am
6-K
zc5jg6wa1boz gm41
26 May 22
Current report (foreign)
5:11pm
6-K
ba398v3 y3064z
26 May 22
Current report (foreign)
4:11pm
6-K
xgxw5jr4hlvcgikx
25 May 22
Current report (foreign)
4:11pm